Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June
2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's …

Alzheimer's disease (AD) is a chronic neurodegenerative disease, with the characteristics of
neurofibrillary tangle (NFT) and senile plaque (SP) formation. Although great progresses …

According to the β-amyloid (Aβ) hypothesis of Alzheimer's disease (AD), brain Aβ
accumulation is the primary cascade event leading to cognitive deficit and dementia …

Over the past 30 years, the majority of (pre) clinical efforts to find an effective therapy for
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …

Abstract On June 7th 2021, the Food and Drug Administration (FDA) granted approval for
Aduhelm (aducanumab) for the treatment of Alzheimer's disease under its accelerated …

The dominant protein-lowering strategy in Alzheimer's Disease (AD) has failed to provide a
clinically-meaningful treatment for patients. We hypothesize that the loss of functional …

Background: In amyloid-positive individuals at risk for Alzheimer's disease (AD), high
soluble 42-amino acid amyloid-ß (Aß42) levels are associated with normal cognition. It is …

Background In recent years, longitudinal studies of Alzheimer's disease (AD) have been
successively concluded. Our aim is to determine the efficacy of amyloid‐β (Aβ) PET in …

Despite presence of substantial evidence suggesting the pivotal role of amyloid (Aβ) in
Alzheimer's disease (AD), very few therapeutic agents have been able to ameliorate the …